Abstract
Introduction

Protein kinase C (PKC) isozymes emerge as important potential therapeutic targets in chronic cardiovascular diseases
and in particular, heart failure (HF) [2] . However, individual PKC isozymes play different roles in the pathogenesis of cardiac diseases [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . [4] ; an effect that is supported by data from a recent clinical trial (phase IIa) in humans [15] . However, treating hypertensive rats exhibiting HF with ␦V1-1 did not improve cardiac function whereas εV1-2, a specific PKCε inhibitor peptide, prevented HF progression in these hypertensive animals [6] . Therefore, different PKC isozymes have unique role in various cardiac diseases and the use of isozyme selective pharmacological agents is more useful than using general PKC inhibitors or activators in assessing the role of PKC in these pathologies.
For instance, PKC␦ activation augments cardiac reperfusion damage after acute myocardial infarction (MI) and inhibition of PKC␦ with
␦V1-1, a specific peptide inhibitor of PKC␦, reduces infarct size and cardiac dysfunction in a porcine model
Cardiac remodelling is an essential component in the process of HF progression [16] . It involves both adaptive and maladaptiveadverse remodelling and further loss of function. It has long been suggested that decreasing the excessive remodelling events of the failing myocardium should decrease myocardial dysfunction [17] .
In an earlier study, we reported that PKC␤I and ␤II levels are elevated in the failing hearts of rats with sustained hypertension, and that angiotensin receptor blocker treatment improved cardiac function presumably by attenuating PKC␤I and ␤II [5] . Further, in a recent study, we found that both acute and chronic inhibition of PKC␤II 
improved cardiac contractility and calcium handling in rats with hypertension-induced cardiac dysfunction as well Langendorff preparation (under Revision). Here we focused on the effects of PKC␤II inhibition on cardiac fibrosis and inflammation in this post-MI HF model.
Materials and methods
Treatment protocol for post-MI HF
The left anterior descending (LAD) coronary artery of male Wistar rats was occluded to induce MI, as described elsewhere [18] (see also Fig. 1A [19] .
Evaluation of myocardial fibrosis
Paraffin-embedded mid-ventricle sections of the myocardium were dewaxed by series of xylene and ethanol, and then rehydrated. Further, these sections were stained with picrosirius red; collagen deposition, an index of myocardial fibrosis, was observed and quantified by using a computer-assisted morphometric system (Leica Quantimet 500, Cambridge, UK) [20] . At least 20 fields per slide were counted for each group. 
Evaluation of infiltration of inflammatory cells
Evaluation of mast cell density and degranulation
Toluidine blue was used to stain mast cells, as described previously [21] . Briefly 
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Fig. 1 (A) Heart failure (HF) induction and treatment protocol. Twelve-week-old rats were subjected to myocardial infarction (MI) by left anterior descending coronary artery ligation. Four weeks after MI induction, the rats were treated with the PKC␤II-specific inhibitor, ␤IIV5-3, or with control (TAT-carrier peptide). Peptide treatment was continuous (for 6 weeks) using subcutaneous Alzet pump delivery at 3/mg/kg/day. (B) Representative blots showing the levels of cardiac PKC␤I and ␤II in the total and particulate fraction (triton soluble) from sham-operated normal rats or post-MI HF rats treated with TAT or ␤IIV5-3. Note an increase in PKC␤II but not PKC␤I in the particulate fraction of failed hearts and a selective loss of PKC␤II increase in this fraction from rats treated with
Results
PKC␤II inhibition by ␤IIV5-3 attenuates cardiac hypertrophy in post-MI-induced end-stage HF
Sustained treatment of rats with the PKC␤II-specific inhibitor, ␤IIV5-3 [22] selectively inhibited PKC␤II activity as determined by a reduction in translocation of this isozyme to the particulate fraction; this treatment had no effect on PKC␤I translocation in MI HF rats (Fig. 1B) (Fig. 1D) (Fig. 1F) .
PKC␤II inhibition by ␤IIV5-3 suppresses myocardial fibrosis in post-MI-induced end-stage HF
On week 22, 10 weeks after infarction, collagen deposition, an index of myocardial fibrosis, was more pronounced in the peri-infarcted area, as compared with the remote area ( Fig. 2A) . [24, 25] . Fig. 4B and B1) Fig. 4A and A1) . However, after 6 weeks of ␤IIV5-3 treatment, inflammatory cell infiltration was significantly inhibited in rats with post-MI-induced end-stage HF (Fig. 4C and C1 ). [26] . A two-fold increase in mast cell density ( Fig. 5B and D) and a two-fold increase in mast cell degranulation ( Fig. 5F and H) (Fig. 5F ) whereas fewer degranulated mast cells were found in the endocardial regions in any of the three groups (Fig. 5A-C) . (Fig. 1D and Table 1) .
No differences in infarcted area were observed between post-MI HF groups (Fig. 2B). When examining the remote area, collagen deposition was significantly elevated in the TAT-treated post-MI rats, as compared with TAT-treated sham-operated rats (Fig. 2C-E and F). Treatment with ␤IIV5-3 resulted in a significant decrease in collagen deposition in the remote area. Increased myocardial fibrosis is due, at least in part, to an increase in TGF␤1 levels and a subsequent activation of SMADsignalling cascades [23]. We found that myocardial levels of active TGF␤1 and phospho SMAD2/3 increased in post-MI TAT-treated hearts as compared with sham-operated rats (Fig. 3A-D). A 6-week treatment of rats with HF with ␤IIV5-3 significantly attenuated the increase in both TGF␤1 and phospho SMAD2/3 level in the remote area of the left ventricle (Fig. 3A-D). Upon quantification, we found that the percentage of phospho SMAD2/3-positive nuclei in post-MI TAT-treated hearts increased as compared with sham-operated rats (222 Ϯ 8 versus 100 Ϯ 2), whereas treatment with ␤IIV5-3 resulted in a significant decrease in phospho SMAD2/3-positive nuclei (89 Ϯ 2) (not shown in figure).
PKC␤II inhibition by ␤IIV5-3 reduces myocardial inflammation in post-MI-induced end-stage HF
Infiltrating inflammatory cells in the myocardium contribute to cardiac remodelling through secretion of cytokines
Histochemical analyses demonstrated peri-vascular inflammation throughout the myocardium, predominantly in the peri-infarct region. Our analysis suggested that apart from the peri-vascular region, myocardial inflammation was increased in the epicardium in rats with HF (
PKC␤II inhibition by ␤IIV5-3 decreases cardiac mast cell density and mast cell degranulation in post-MI-induced end-stage HF
Mast cells reside close to blood vessels in the myocardium and are important contributors to cardiac pathology as they release pro-fibrogenic, pro-inflammatory and pro-hypertrophic factors upon stimulation
Discussion
In this study, we analysed myocyte hypertrophy, myocardial fibrosis, cardiac inflammation and mast cell degranulation in a region remote from the infarcted area. We hypothesized that remodelling of the remote area as induced by MI contributed to cardiac dysfunction. Indeed, with the use of the PKC␤II-selective inhibitor, ␤IIV5-3, remodelling in the remote area was blunted and cardiac function was improved in a rat model of post-MI HF. In this model, rats were subjected to MI and developed symptoms of end-stage HF. A 6-week treatment with ␤IIV5-3, initiated 4 weeks after MI induction, attenuated cardiac dysfunction, myocyte hypertrophy, collagen deposition, myocardial inflammation and mast cell density and degranulation. In addition, PKC␤II inhibition normalized both right and left ventricles wall thickness
In hearts of patients with HF, both PKC␤I and II levels are higher relative to age-matched normal hearts [8] . A more recent study also reported increased expression of PKC␤II in end-stage human HF (dilated cardiomyopathy) [10] . Similarly, we also found a 50% increase in PKC␤II activity in the myocardium of rats with end-stage HF ( ( Fig. 1B) . As expected, after 6-week treatment, the PKC␤II-specific inhibitor ␤IIV5-3 did not affect the levels or activity of PKC␤I, whereas it completely blunted the activation of PKC␤II (Fig. 1B) . [11] . Moreover, activated overexpression of PKC␤II was lethal in neonatal mice, whereas in adult mice it induced hypertrophy and affected cardiac contractility [27] . These studies show the importance of PKC␤II in cardiac hypertrophy in mice. In contrast, in one study, PKC␤ KO mice showed no cardiac symptoms [28] [29] . A similar reduction in myocardial fibrosis (collagen deposition) following treatment with a specific PKC␤II inhibitor has been observed by us in the [23] . We found that fibroblast stimulation and collagen release was inhibited by chronic treatment with ␤IIV5-3 (Fig. 2) 
